Virosome presents multimodel cancer therapy without viral replication

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Saga, Kotaro ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; VIROSOME;

CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; INFLUENZA A VIRUS; INFLUENZA VIRUS A; NEOPLASM; NEOPLASMS; PATHOLOGY; REVIEW;

DRUG DELIVERY SYSTEMS; HUMANS; INFLUENZA A VIRUS; MEMBRANE PROTEINS; NEOPLASMS; VIROSOMES;

MLCS; MLOWN;

EID: 84893756119     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/764706     Document Type: Review

References (114)

1. Burch P. A., Croghan G. A., Gastineau D. A., Jones L. A., Kaur J. S., Kylstra J. W., Richardson R. L., Valone F. H., Vuk-Pavlović S., Immunotherapy (APC8015, provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004 60 3 197 (Pubitemid 38971831)
2. Cheever M. A., Higano C. S., PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clinical Cancer Research 2011 17 11 3520 3526 2-s2.0-79957879852 10.1158/1078-0432.CCR-10-3126
3. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
4. Prieto P. A., Yang J. C., Sherry R. M., Hughes M. S., Kammula U. S., White D. E., Levy C. L., Rosenberg S. A., Phan G. Q., CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research 2012 18 7 2039 2047 2-s2.0-84859393995 10.1158/1078-0432.CCR-11-1823
5. Topalian S. L., Hodi F. S., Brahmer J. R., Gettinger S. N., Smith D. C., McDermott D. F., Powderly J. D., Carvajal R. D., Sosman J. A., Atkins M. B., Leming P. D., Spigel D. R., Antonia S. J., Horn L., Drake C. G., Pardoll D. M., Chen L., Sharfman W. H., Anders R. A., Taube J. M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012 366 26 2443 2454 10.1056/NEJMoa1200690
6. Wang R.-F., Human tumor antigens: implications for cancer vaccine development. Journal of Molecular Medicine 1999 77 9 640 655 2-s2.0-0032736018 10.1007/s001099900042 (Pubitemid 29500957)
7. Call K. M., Glaser T., Ito C. Y., Buckler A. J., Pelletier J., Haber D. A., Rose E. A., Kral A., Yeger H., Lewis W. H., Jones C., Housman D. E., Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990 60 3 509 520 2-s2.0-0025099787 10.1016/0092-8674(90)90601-A (Pubitemid 20060879)
8. Gessler M., Poustka A., Cavenee W., Neve R. L., Orkin S. H., Bruns G. A. P., Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990 343 6260 774 778 2-s2.0-0025098654 10.1038/343774a0 (Pubitemid 20065258)
9. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 5038 1643 1647 2-s2.0-0026322151 (Pubitemid 21917508)
10. Peiper M., Goedegebuure P. S., Izbicki J. R., Eberlein T. J., Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Anticancer Research 1999 19 4 2471 2475 2-s2.0-0032815539 (Pubitemid 29392394)
11. Peiper M., Goedegebuure P. S., Linehan D. C., Ganguly E., Douville C. C., Eberlein T. J., The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. European Journal of Immunology 1997 27 5 1115 1123 2-s2.0-0030898155 (Pubitemid 27197213)
12. Holliger P., Manzke O., Span M., Hawkins R., Fleischmann B., Qinghua L., Wolf J., Diehl V., Cochet O., Winter G., Bohlen H., Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 × anti-CEA bispecific diabodies and B7 × anti- CEA bispecific fusion proteins. Cancer Research 1999 59 12 2909 2916 2-s2.0-0033564804 (Pubitemid 29283131)
13. Oka Y., Elisseeva O. A., Tsuboi A., Ogawa H., Tamaki H., Li H., Oji Y., Kim E. H., Soma T., Asada M., Ueda K., Maruya E., Saji H., Kishimoto T., Udaka K., Sugiyama H., Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000 51 2 99 107 2-s2.0-0034112824 (Pubitemid 30150969)
14. Germain R. N., MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994 76 2 287 299 2-s2.0-0028038426 10.1016/0092-8674(94)90336-0
15. Jondal M., Schirmbeck R., Reimann J., MHC class I-restricted CTL responses to exogenous antigens. Immunity 1996 5 4 295 302 2-s2.0-0030273342 10.1016/S1074-7613(00)80255-1 (Pubitemid 26366752)
16. Mellman I., Turley S. J., Steinman R. M., Antigen processing for amateurs and professionals. Trends in Cell Biology 1998 8 6 231 237 2-s2.0-0032101743 10.1016/S0962-8924(98)01276-8 (Pubitemid 28243205)
17. Cresswell P., Ackerman A. L., Giodini A., Peaper D. R., Wearsch P. A., Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunological Reviews 2005 207 145 157 2-s2.0-26244455510 10.1111/j.0105-2896. 2005.00316.x (Pubitemid 41415014)
18. Marchand M., van Baren N., Weynants P., Brichard V., Dréno B., Tessier M. H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Liénard D., Beauduin M., Dietrich P. Y., Russo V., Kerger J., Masucci G., Jäger E., De Greve J., Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. British Journal of Cancer 1999 80 219 230 10.1038/sj.bjc.6690342 (Pubitemid 29210109)
19. Kershaw M. H., Westwood J. A., Darcy P. K., Gene-engineered T cells for cancer therapy. Nature Reviews Cancer 2013 13 525 541 10.1038/nrc3565
20. Li C.-Y., Huang Q., Kung H.-F., Cytokine and immuno-gene therapy for solid tumors. Cellular & Molecular Immunology 2005 2 2 81 91 2-s2.0-32944479702
21. Fillat C., Carrió M., Cascante A., Sangro B., Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Current Gene Therapy 2003 3 1 13 26 2-s2.0-0037832252
22. Roth J. A., Adenovirus p53 gene therapy. Expert Opinion on Biological Therapy 2006 6 1 55 61 2-s2.0-30044439886 10.1517/14712598.6.1.55 (Pubitemid 43049346)
23. Kirn D., Martuza R. L., Zwiebel J., Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nature Medicine 2001 7 7 781 787 2-s2.0-0034927057 10.1038/89901 (Pubitemid 32691631)
24. Lorence R. M., Rood P. A., Kelley K. W., Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor- α and augmentation of its cytotoxicity. Journal of the National Cancer Institute 1988 80 16 1305 1312 2-s2.0-0023723833
25. Coffey M. C., Strong J. E., Forsyth P. A., Lee P. W. K., Reovirus therapy of tumors with activated Ras pathway. Science 1998 282 5392 1332 1334 2-s2.0-0032515141 (Pubitemid 28524498)
26. Martuza R. L., Malick A., Markert J. M., Ruffner K. L., Coen D. M., Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991 252 5007 854 856 2-s2.0-0025864440 (Pubitemid 121000529)
27. Bischoff J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A., McCormick F., An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996 274 5286 373 376 2-s2.0-0344188096 10.1126/science.274.5286.373 (Pubitemid 26353341)
28. Mastrangelo M. J., Maguire H. C. Jr., Eisenlohr L. C., Laughlin C. E., Monken C. E., McCue P. A., Kovatich A. J., Lattime E. C., Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Therapy 1999 6 5 409 422 2-s2.0-0033193127 (Pubitemid 129667814)
29. Thorne S. H., Hwang T.-H. H., O'Gorman W. E., Bartlett D. L., Sei S., Kanji F., Brown C., Werier J., Cho J.-H., Lee D.-E., Wang Y., Bell J., Kirn D. H., Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. The Journal of Clinical Investigation 2007 117 11 3350 3358 2-s2.0-36049009021 10.1172/JCI32727 (Pubitemid 350096991)
30. Earp L. J., Delos S. E., Park H. E., White J. M., Marsh D. M., The many mechanisms of viral membrane fusion proteins. Membrane Trafficking in Viral Replication 2005 Berlin, Germany Springer 25 66
31. Almeida J., Edwards D. C., Brand C., Heath T., Formation of virosomes from influenza subunits and liposomes. The Lancet 1975 306 899 901
32. Zurbriggen R., Immunostimulating reconstituted influenza virosomes. Vaccine 2003 21 9-10 921 924 2-s2.0-0037435877 10.1016/S0264-410X(02)00541-8 (Pubitemid 36126427)
33. Yamada T., Iwasaki Y., Tada H., Iwabuki H., Chuah M. K. L., VandenDriessche T., Fukuda H., Kondo A., Ueda M., Seno M., Tanizawa K., Kuroda S., Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature Biotechnology 2003 21 8 885 890 2-s2.0-12444252075 10.1038/nbt843 (Pubitemid 36936193)
34. Cornet B., Vandenbranden M., Cogniaux J., Giurgea L., Dekegel D., Ruysschaert J. M., Virosomes reconstituted from human immunodeficiency virus proteins and lipids. Biochemical and Biophysical Research Communications 1990 167 1 222 231 2-s2.0-0025234542 10.1016/0006-291X(90)91754-G (Pubitemid 20085373)
35. Kapczynski D. R., Tumpey T. M., Development of a virosome vaccine for Newcastle disease virus. Avian Diseases 2003 47 3 578 587 2-s2.0-0141683617 (Pubitemid 37156003)
36. Uchida T., Kim J., Yamaizumi M., Miyake Y., Okada Y., Reconstitution of lipid vesicles associated with HVJ (Sendai virus) spikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin. Journal of Cell Biology 1979 80 1 10 20 2-s2.0-0018417571 (Pubitemid 9097504)
37. Kaneda Y., Nakajima T., Nishikawa T., Yamamoto S., Ikegami H., Suzuki N., Nakamura H., Morishita R., Kotani H., Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Molecular Therapy 2002 6 2 219 226 2-s2.0-0036664449 10.1006/mthe.2002.0647 (Pubitemid 36336129)
38. Felnerova D., Viret J.-F., Glück R., Moser C., Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current Opinion in Biotechnology 2004 15 6 518 529 2-s2.0-9244234954 10.1016/j.copbio.2004.10.005 (Pubitemid 39551004)
39. Lund P. E., Hunt R. C., Gottesman M. M., Kimchi-Sarfaty C., Pseudovirions as vehicles for the delivery of siRNA. Pharmaceutical Research 2010 27 3 400 420 2-s2.0-77949271472 10.1007/s11095-009-0012-2
40. Moser C., Metcalfe I. C., Viret J.-F., Virosomal adjuvanted antigen delivery systems. Expert Review of Vaccines 2003 2 2 189 196 2-s2.0-0037847495 10.1586/14760584.2.2.189 (Pubitemid 36559924)
41. Suarez D. L., Schultz-Cherry S., Immunology of avian influenza virus: a review. Developmental and Comparative Immunology 2000 24 2-3 269 283 2-s2.0-0034163283 10.1016/S0145-305X(99)00078-6 (Pubitemid 30136306)
42. Noda T., Kawaoka Y., Structure of influenza virus ribonucleoprotein complexes and their packaging into virions. Reviews in Medical Virology 2010 20 6 380 391 2-s2.0-77958569432 10.1002/rmv.666
43. Skehel J. J., Wiley D. C., Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Review of Biochemistry 2000 69 531 569 2-s2.0-0033783032 10.1146/annurev.biochem.69.1.531
44. Fukuyama S., Kawaoka Y., The pathogenesis of influenza virus infections: the contributions of virus and host factors. Current Opinion in Immunology 2011 23 4 481 486 2-s2.0-81155159753 10.1016/j.coi.2011.07.016
45. Cross K. J., Burleigh L. M., Steinhauer D. A., Mechanisms of cell entry by influenza virus. Expert Reviews in Molecular Medicine 2001 3 1 18 10.1017/S1462399401002575
46. Yoshimura A., Kuroda K., Kawasaki K., Yamashina S., Maeda T., Ohnishi S. I., Infectious cell entry mechanism of influenza virus. Journal of Virology 1982 43 1 284 293 2-s2.0-0019952878 (Pubitemid 12084906)
47. Bron R., Ortiz A., Dijkstra J., Stegmann T., Wilschut J., Duzgunees N., Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods in Enzymology 1993 San Diego, Calif, USA Academic Press 313 331
48. Stegmann T., Morselt H. W., Booy F. P., van Breemen J. F., Scherphof G., Wilschut J., Functional reconstitution of influenza virus envelopes. The EMBO Journal 1987 6 9 2651 2659 2-s2.0-0023402744
49. Bron R., Ortiz A., Wilschut J., Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). Biochemistry 1994 33 31 9110 9117 2-s2.0-0028085720 (Pubitemid 24272861)
50. Glück R., Mischler R., Finkel B., Que J. U., Scarpa B., Cryz S. J. Jr., Immunogenicity of new virosome influenza vaccine in elderly people. The Lancet 1994 344 8916 160 163 2-s2.0-0028244249 10.1016/S0140-6736(94)92758-8 (Pubitemid 24218879)
51. Mischler R., Metcalfe I. C., Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002 20 5 B17 B23 2-s2.0-0037146955 10.1016/S0264-410X(02)00512-1 (Pubitemid 35435392)
52. Zurbriggen R., Glück R., Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 1999 17 11-12 1301 1305 2-s2.0-0345003993 10.1016/S0264-410X(98)00361-2 (Pubitemid 29138795)
53. Zurbriggen R., Novak-Hofer I., Seelig A., Glück R., IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Progress in Lipid Research 2000 39 1 3 18 2-s2.0-0034014999 10.1016/S0163- 7827(99)00017-X (Pubitemid 30145440)
54. Pöltl-Frank F., Zurbriggen R., Helg A., Stuart F., Robinson J., Glück R., Pluschke G., Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clinical and Experimental Immunology 1999 117 3 496 503 2-s2.0-0006981144 10.1046/j.1365-2249.1999.00989.x (Pubitemid 29398296)
55. Correale P., Cusi M. G., Sabatino M., Micheli L., Pozzessere D., Nencini C., Valensin P. E., Petrioli R., Giorgi G., Zurbriggen R., Gluck R., Francini G., Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. European Journal of Cancer 2001 37 16 2097 2103 2-s2.0-0034784120 10.1016/S0959-8049(01)00241-6 (Pubitemid 32938115)
56. Cusi M. G., del Vecchio M. T., Terrosi C., Savellini G. G., Di Genova G., La Placa M., Fallarino F., Moser C., Cardone C., Giorgi G., Francini G., Correale P., Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. Journal of Immunology 2005 174 11 7210 7216 2-s2.0-21044459831 (Pubitemid 40705689)
57. Yang Y., Wilson J. M., CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996 273 5283 1862 1864 2-s2.0-0029780119 (Pubitemid 26322496)
58. Schoenberger S. P., Toes R. E. M., van Dervoort E. I. H., Offringa R., Melief C. J. M., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD4OL interactions. Nature 1998 393 6684 480 483 2-s2.0-0032482474
59. Bungener L., Serre K., Bijl L., Leserman L., Wilschut J., Daemen T., Machy P., Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002 20 17-18 2287 2295 2-s2.0-0037157276 10.1016/S0264-410X(02)00103-2 (Pubitemid 34497039)
60. Angel J., Chaperot L., Molens J.-P., Mezin P., Amacker M., Zurbriggen R., Grichine A., Plumas J., Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 2007 25 19 3913 3921 2-s2.0-34247244107 10.1016/j.vaccine.2007.01.101 (Pubitemid 46613829)
61. Correale P., del Vecchio M. T., Renieri T., Genova G. D., Placa M. L., Remondo C., Savellini G. G., Terrosi C., Zurbriggen R., Amacker M., Francini G., Cusi M. G., Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. Cancer Letters 2008 263 2 291 301 2-s2.0-41649084521 10.1016/j.canlet.2008.01.018
62. Mastrobattista E., Schoen P., Wilschut J., Crommelin D. J. A., Storm G., Targeting influenza virosomes to ovarian carcinoma cells. FEBS Letters 2001 509 1 71 76 2-s2.0-0035976879 10.1016/S0014-5793(01)03112-X (Pubitemid 33153083)
63. Schoen P., Leserman L., Wilschut J., Fusion of reconstituted influenza virus envelopes with liposomes mediated by streptavidin/biotin interactions. FEBS Letters 1996 390 3 315 318 2-s2.0-0030605811 10.1016/0014-5793(96)00682-5 (Pubitemid 26248967)
64. Waelti E., Wegmann N., Schwaninger R., Wetterwald A., Wingenfeld C., Rothen-Rutishauser B., Gimmi C. D., Targeting HER-2/neu with antirat neu virosomes for cancer therapy. Cancer Research 2002 62 2 437 444 2-s2.0-0037081281 (Pubitemid 34106416)
65. Jamali A., Holtrop M., de Haan A., Hashemi H., Shenagari M., Memarnejadian A., Roohvand F., Sabahi F., Kheiri M. T., Huckriede A., Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunology Letters 2012 148 1 77 82 10.1016/j.imlet.2012.08.006
66. Wiedermann U., Wiltschke C., Jasinska J., Kundi M., Zurbriggen R., Garner-Spitzer E., Bartsch R., Steger G., Pehamberger H., Scheiner O., Zielinski C. C., A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Research and Treatment 2010 119 3 673 683 2-s2.0-74849113525 10.1007/s10549-009-0666-9
67. Curran J., Kolakofsky D., Replication of paramyxoviruses. Advances in Virus Research 1999 54 403 422 2-s2.0-0032651115
68. Okada Y., Duzgunes N., Sendai virus-induced cell fusion. Methods in Enzymology 1993 San Diego, Calif, USA Academic Press 18 41 (Pubitemid 23264575)
69. Takimoto T., Taylor G. L., Connaris H. C., Crennell S. J., Portner A., Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. Journal of Virology 2002 76 24 13028 13033 2-s2.0-0036891868 10.1128/JVI.76.24.13028-13033.2002 (Pubitemid 35386986)
70. Asano A., Asano K., Viral proteins in cell fusion. Tokai Journal of Experimental and Clinical Medicine 1982 7 supplement 193 196 2-s2.0-0020451866
71. Haywood A. M., Boyer B. P., Sendai virus membrane fusion: time course and effect of temperature, pH, calcium, and receptor concentration. Biochemistry 1982 21 24 6041 6046 2-s2.0-0020423059 (Pubitemid 13141609)
72. Kaneda Y., Saeki Y., Morishita R., Gene therapy using HVJ-liposomes: the best of both worlds? Molecular Medicine Today 1999 5 7 298 303 2-s2.0-0033167922 10.1016/S1357-4310(99)01482-3 (Pubitemid 29302677)
73. Kaneda Y., New vector innovation for drug delivery: development of fusigenic non-viral particles. Current Drug Targets 2003 4 8 599 602 2-s2.0-0141919523 10.2174/1389450033490740 (Pubitemid 37236374)
74. Shimamura M., Morishita R., Endoh M., Oshima K., Aoki M., Waguri S., Uchiyama Y., Kaneda Y., HVJ-envelope vector for gene transfer into central nervous system. Biochemical and Biophysical Research Communications 2003 300 2 464 471 2-s2.0-0037427491 10.1016/S0006-291X(02)02807-3 (Pubitemid 38375832)
75. Oshima K., Shimamura M., Mizuno S., Tamai K., Doi K., Morishita R., Nakamura T., Kubo T., Kaneda Y., Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats. The FASEB Journal 2004 18 1 212 214 2-s2.0-1342332145
76. Kim Y. D., Park K.-G., Morishita R., Kaneda Y., Kim S.-Y., Song D.-K., Kim H.-S., Nam C.-W., Lee H. C., Lee K.-U., Park J.-Y., Kim B.-W., Kim J.-G., Lee I.-K., Liver-directed gene therapy of diabetic rats using an HVJ-E vector containing EBV plasmids expressing insulin and GLUT 2 transporter. Gene Therapy 2006 13 3 216 224 2-s2.0-31444444251 10.1038/sj.gt.3302644 (Pubitemid 43148644)
77. Ito M., Yamamoto S., Nimura K., Hiraoka K., Tamai K., Kaneda Y., Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. Journal of Gene Medicine 2005 7 8 1044 1052 2-s2.0-23344453535 10.1002/jgm.753 (Pubitemid 41195066)
78. Kawano H., Komaba S., Kanamori T., Kaneda Y., A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. BMC Medicine 2007 5, article 28 2-s2.0-35448965200 10.1186/1741-7015-5-28 (Pubitemid 47629351)
79. Ziegler J. L., Spontaneous remission in Burkitt's lymphoma. National Cancer Institute Monographs 1976 44 61 65 (Pubitemid 8036458)
80. Asada T., Treatment of human cancer with mumps virus. Cancer 1974 34 6 1907 1928 2-s2.0-0016358317
81. Kelly E., Russell S. J., History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy 2007 15 4 651 659 2-s2.0-33947245441 10.1038/sj.mt.6300108 (Pubitemid 46431984)
82. Davis J. J., Fang B., Oncolytic virotherapy for cancer treatment: challenges and solutions. Journal of Gene Medicine 2005 7 11 1380 1389 2-s2.0-27944497796 10.1002/jgm.800 (Pubitemid 41672396)
83. Kirn D. H., Thorne S. H., Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nature Reviews Cancer 2009 9 1 64 71 2-s2.0-57749201655 10.1038/nrc2545
84. Liu T.-C., Kirn D., Gene therapy progress and prospects cancer: oncolytic viruses. Gene Therapy 2008 15 12 877 884 2-s2.0-44849135037 10.1038/gt.2008.72 (Pubitemid 351791475)
85. Msaouel P., Iankov I. D., Allen C., Morris J. C., Von Messling V., Cattaneo R., Koutsilieris M., Russell S. J., Galanis E., Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009 69 1 82 91 2-s2.0-58149345608 10.1002/pros.20857
86. Kurooka M., Kaneda Y., Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Research 2007 67 1 227 236 2-s2.0-33846432377 10.1158/0008-5472.CAN-06-1615 (Pubitemid 46142779)
87. Matsushima-Miyagi T., Hatano K., Nomura M., Li-Wen L., Nishikawa T., Saga K., Shimbo T., Kaneda Y., TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clinical Cancer Research 2012 18 22 6271 6283 10.1158/1078-0432.CCR-12-1595
88. + immunoregulatory cells. Journal of Immunology 2001 167 3 1137 1140 2-s2.0-0035421654 (Pubitemid 32703105)
89. + regulatory T cells in immunological tolerance to self and non-self. Nature Immunology 2005 6 4 345 352 2-s2.0-16844365788 10.1038/ni1178 (Pubitemid 41716771)
90. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003 98 5 1089 1099 2-s2.0-0041386189 10.1002/cncr.11618 (Pubitemid 37022112)
91. Lund J. M., Alexopoulou L., Sato A., Karow M., Adams N. C., Gale N. W., Iwasaki A., Flavell R. A., Recognition of single-stranded RNA viruses by toll-like receptor 7. Proceedings of the National Academy of Sciences of the United States of America 2004 101 15 5598 5603 2-s2.0-1842631428 10.1073/pnas.0400937101 (Pubitemid 38481202)
92. Triantafilou K., Orthopoulos G., Vakakis E., Ahmed M. A. E., Golenbock D. T., Lepper P. M., Triantafilou M., Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly toll-like receptor (TLR) 8-dependent. Cellular Microbiology 2005 7 8 1117 1126 2-s2.0-22744457707 10.1111/j.1462-5822.2005.00537.x (Pubitemid 41030937)
93. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K. J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.-S., Reis E Sousa C., Matsuura Y., Fujita T., Akira S., Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006 441 1 101 105 2-s2.0-33646342149 10.1038/nature04734
94. Suzuki H., Kurooka M., Hiroaki Y., Fujiyoshi Y., Kaneda Y., Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Letters 2008 582 9 1325 1329 2-s2.0-41449106876 10.1016/j.febslet.2008.03.011
95. Fujihara A., Kurooka M., Miki T., Kaneda Y., Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunology, Immunotherapy 2008 57 1 73 84 2-s2.0-35748961970 10.1007/s00262-007-0351-y (Pubitemid 350043650)
96. Kawaguchi Y., Miyamoto Y., Inoue T., Kaneda Y., Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. International Journal of Cancer 2009 124 10 2478 2487 2-s2.0-64249091007 10.1002/ijc.24234
97. Seth R. B., Sun L., Ea C.-K., Chen Z. J., Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF- B and IRF3. Cell 2005 122 5 669 682 2-s2.0-24144461689 10.1016/j.cell.2005.08.012 (Pubitemid 41242633)
98. Holoch P. A., Griffith T. S., TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. European Journal of Pharmacology 2009 625 1-3 63 72 2-s2.0-71749102407 10.1016/j.ejphar.2009.06.066
99. Ploner C., Kofler R., Villunger A., Noxa: at the tip of the balance between life and death. Oncogene 2008 27 supplement 1 S84 S92 2-s2.0-68149153007 10.1038/onc.2009.46
100. Eitz Ferrer P., Potthoff S., Kirschnek S., Gasteiger G., Kastenmüller W., Ludwig H., Paschen S. A., Villunger A., Sutter G., Drexler I., Häcker G., Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN- β -dependent induction of pro-apoptotic Noxa. PLoS Pathogens 2011 7 6 e1002083 2-s2.0-80455140310
101. Romieu-Mourez R., Solis M., Nardin A., Goubau D., Baron-Bodo V., Lin R., Massie B., Salcedo M., Hiscott J., Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Research 2006 66 21 10576 10585 2-s2.0-33751301603 10.1158/0008-5472.CAN-06-1279 (Pubitemid 44799781)
102. Valentine M. T., Fordyce P. M., Block S. M., Eg5 steps it up! Cell Division 2006 1, article 31 2-s2.0-34248331788 10.1186/1747-1028-1-31 (Pubitemid 46731026)
103. Blangy A., Lane H. A., d'Hérin P., Harper M., Kress M., Nigg E. A., Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995 83 7 1159 1169 2-s2.0-0029417238
104. Matsuda M., Yamamoto T., Matsumura A., Kaneda Y., Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Therapy 2009 16 12 1465 1476 2-s2.0-73849147949 10.1038/gt.2009.99
105. Matsuda M., Nimura K., Shimbo T., Hamasaki T., Yamamoto T., Matsumura A., Kaneda Y., Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. Journal of Neuro-Oncology 2011 103 1 19 31 2-s2.0-79960022868 10.1007/s11060-010-0355-x
106. Villar E., Barroso I. M., Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconjugate Journal 2006 23 1-2 5 17 2-s2.0-33645456588 10.1007/s10719-006-5433-0
107. Nomura M., Shimbo T., Miyamoto Y., Fukuzawa M., Kaneda Y., 13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma. Cancer Science 2013 104 2 238 244 10.1111/cas.12063
108. Shimbo T., Kawachi M., Saga K., Fujita H., Yamazaki T., Tamai K., Kaneda Y., Development of a transferrin receptor-targeting HVJ-E vector. Biochemical and Biophysical Research Communications 2007 364 3 423 428 2-s2.0-35648993476 10.1016/j.bbrc.2007.09.135 (Pubitemid 350026486)
109. Saga K., Tamai K., Kawachi M., Shimbo T., Fujita H., Yamazaki T., Kaneda Y., Functional modification of Sendai virus by siRNA. Journal of Biotechnology 2008 133 3 386 394 2-s2.0-37549057360 10.1016/j.jbiotec.2007.10.003 (Pubitemid 50018953)
110. Benveniste E. N., Cytokine actions in the central nervous system. Cytokine and Growth Factor Reviews 1998 9 3-4 259 275 2-s2.0-0345580623 10.1016/S1359-6101(98)00015-X (Pubitemid 29019710)
111. Colombo M. P., Trinchieri G., Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine and Growth Factor Reviews 2002 13 2 155 168 2-s2.0-0036005890 10.1016/S1359-6101(01)00032-6 (Pubitemid 34229390)
112. Watford W. T., Moriguchi M., Morinobu A., O'Shea J. J., The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine and Growth Factor Reviews 2003 14 5 361 368 2-s2.0-0042375986 10.1016/S1359-6101(03)00043-1 (Pubitemid 37099449)
113. Saga K., Tamai K., Yamazaki T., Kaneda Y., Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN- γ production. Clinical Cancer Research 2013 19 3 668 679 10.1158/1078-0432.CCR-12-1947
114. Meacham C. E., Morrison S. J., Tumour heterogeneity and cancer cell plasticity. Nature 2013 501 328 337 10.1038/nature12624